Metabolic Syndrome and Type 2 Diabetes: Can We Stop the Weight Gain with Diabetes?

Medical Clinics of North America

Volumn 91, Issue 6, 2007, Pages 1107-1123

  Joffe, Denise ^a   Yanagisawa, Robert T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; C PEPTIDE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ANOREXIA; BEHAVIOR MODIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSLIPIDEMIA; EXERCISE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM RETENTION; TREATMENT INDICATION; VOMITING; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; WEIGHT GAIN;

EID: 35448938403     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.06.002     Document Type: Review

References (61)

1. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
2. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366 (2005) 1059-1062
4. Bonora E., Targher G., Formentini F., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 21 (2003) 52-58
5. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
6. The Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes. Diabetes Care 29 (2006) 2701-2707
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
9. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) s4-s42
10. Gerstein H.C., and Haynes R.B. Evidence-based diabetes care (2000), BC Decker, Inc., Ontario (Canada) p. 252-76
11. Williams K.V., and Kelley D.E. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2 (2000) 121-129
12. Klein S., Sheard N.F., Pi-Sunyer X., et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 27 8 (2004) 2067-2073
13. Kim S.H., Lee S.J., Kang E.S., et al. Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 1053-1059
14. Guare J.C., Wing R.R., and Grant A. Comparison of obese NIDDM and non-diabetic women: short and long term weight loss. Obes Res 3 (1995) 329-335
15. Wing R.R., Epstein L.H., Paternostro-Bayles M., et al. Exercise in a behavioral weight control program for obese patients with type 2 diabetes. Diabetologia 31 (1988) 902-909
16. Norris S.L., Zhang X., Avenell A., et al. Long term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 117 (2004) 762-774
17. Nichols G.A., and Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycemic therapies. Diabetes Obes Metab 9 1 (2007) 96-102
18. Flier J.S. Obesity and insulin resistance. J Clin Invest 106 4 (2000) 473-481
19. Purnell J.Q., and Weyer C. Weight effect of current and experimental drugs for diabetes mellitus. Treat Endocrinol 2 1 (2003) 33-47
20. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 32 6 (2006) 910-917
21. Eldor R., Stern E., Milicevic Z., et al. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract 68S1 (2005) S30-S35
22. Rosenstock J., Hassman D.R., Madder R.D., et al. Repaglinide versus nateglinide monotherapy. Diabetes Care 27 (2004) 1265-1270
23. Marbury T., Huang W.C., Strange P., et al. Repaglinide vs. glyburide: a one year comparison trial. Diabetes Res Clin Pract 43 3 (1999) 155-166
24. Vasudevan A.R., and Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy and tolerability. Diabetes Technol Ther 6 6 (2004) 850-863
25. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
26. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 1 (2001) 280-288
27. Aronoff S., Rosenblatt S., Braithwaite S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 11 (2000) 1605-1611
28. Krentz A.J., and Bailey C.J. Oral antidiabetic agents, current role in type 2 diabetes mellitus. Drugs 65 3 (2005) 385-411
29. Hanefield M., Fischer S., Schulze J., et al. Therapeutic potentials of acarbose as first line drug in NIDDM insufficiency treated with diet alone. Diabetes Care 14 8 (1991) 732-737
30. Hotta N., Kakuta H., Sano T., et al. Long-term effect of acarbose on glycemic control in non-insulin dependent diabetes mellitus: a placebo-controlled double blind study. Diabet Med 10 2 (1993) 134-138
31. Wolever T.M., Chiasson J.L., Josse R.G., et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with NIDDM. Int J Obes Relat Metab Disord 21 9 (1997) 756-763
32. Holman R.R., Cull C.A., and Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK prospective diabetes study 44). Diabetes Care 22 6 (1999) 960-964
33. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
34. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with NIDDM. NEJM 333 9 (1995) 541-549
35. Relimpio F., Pumar A., Losada F., et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open label randomized trial. Diabet Med 15 12 (1998) 997-1002
36. Aviles-Santa L., Sindig J., and Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind placebo controlled trial. Ann Intern Med 131 3 (1999) 182-188
37. Stumvoli M., Nurjhan N., Perriello G., et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. NEJM 333 (1995) 550-554
38. Hermann L.S., Schersten B., Bitzen P.O., et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double blind controlled study. Diabetes Care 17 10 (1994) 1100-1109
39. Chaudhuri A., Tomar R., Mohanty P., et al. The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus. Endocr Pract 4 5 (1998) 259-267
40. Ponssen H., Elte J.W.F., Lehert P., et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 22 6 (2000) 709-718
41. Wulffele M.G., Kooy A., Lehert P., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25 (2002) 2133-2140
42. Johnson M, Krosnick A, Carson P, et al. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 20(4):691-8.
43. Fonseca V., Rosenstock J., Patwardhan R., et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283 13 (2000) 1695-1702
44. Rosenstock J., Rood J., Cobitz A., et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 8 6 (2006) 650-660
45. Actos (pioglitazone hydrochloride tablets) (2002), Takeda Chemical Industries LTD., Osaka [data on file]
46. Raskin P., Rendell M., Riddle M.C., et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 7 (2001) 1226-1232
47. Kendall D.M., Kim D., and Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 8 3 (2006) 385-396
48. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
49. Perley M., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic patients. J Clin Invest 46 (1967) 1954-1962
50. Vilsboll T., Krarup T., Deacon C., et al. Reduced post-prandial concentrations of intact biologically active glucagons-like peptide-1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
51. Odegard P.S., Setter S.M., and Iltz J. Update in the pharmacologic treatment of diabetes mellitus. Diabetes Educ 32 5 (2006) 693-711
52. Iltz J, Baker DE, Setter SM, et al. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 28(5):652-65.
53. Exenatide for type 2 diabetes. The Medical Letter 47 1210 (2006) 45-46
54. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
55. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
56. Kendall D., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and sulfonylurea. Diabetes Care 28 (2005) 1083-1091
57. Ratner R.E., Maggs D., Nielsen L.L., et al. Long term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin treated patients with diabetes mellitus. Diabetes Obes Metab 8 (2006) 419-428
58. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143 (2005) 559-569
59. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
60. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 12 (2006) 2638-2643
61. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Theraputics 28 (2006) 1556-1567